Analysts at H.C. Wainwright Maintain their Past ‘Buy’ rating on Shares Fennec Pharmaceuticals Inc (FENC), Set a $18.0000 Price Objective

June 20, 2018 - By Adrian Erickson

Fennec Pharmaceuticals Inc (FENC) Rating Reaffirmed

Equity analysts at H.C. Wainwright now has a $18.0000 price target on Fennec Pharmaceuticals Inc (FENC). H.C. Wainwright and their recent price target would suggest a potential upside of 64.08 % from the company’s previous stock close. The rating has been disclosed in a research note on 19 June.

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Ratings Coverage

Among 2 analysts covering Fennec Pharmaceuticals Inc. – Common Stock (FENC), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Fennec Pharmaceuticals Inc. – Common Stock has $1800 highest and $16 lowest target. $17.50’s average target is 59.53% above currents $10.97 stock price. Fennec Pharmaceuticals Inc. – Common Stock had 5 analyst reports since February 20, 2018 according to SRatingsIntel. H.C. Wainwright maintained the shares of FENC in report on Tuesday, June 19 with “Buy” rating. The firm has “Buy” rating given on Wednesday, May 23 by H.C. Wainwright. H.C. Wainwright maintained Fennec Pharmaceuticals Inc. (NASDAQ:FENC) rating on Monday, April 2. H.C. Wainwright has “Buy” rating and $1800 target.

The stock increased 0.09% or $0.01 during the last trading session, reaching $10.97. About 42,771 shares traded. Fennec Pharmaceuticals Inc. (FENC) has risen 191.86% since June 20, 2017 and is uptrending. It has outperformed by 179.29% the S&P500.

Analysts await Fennec Pharmaceuticals Inc. (NASDAQ:FENC) to report earnings on August, 10. They expect $-0.10 earnings per share, up 9.09 % or $0.01 from last year’s $-0.11 per share. After $-0.09 actual earnings per share reported by Fennec Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts 11.11 % negative EPS growth.

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. The company has market cap of $203.81 million. The Company’s lead product candidate is the Sodium Thiosulfate, a water soluble thiol compound that acts as a chemical reducing agent, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. It currently has negative earnings. The firm was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014.

More news for Fennec Pharmaceuticals Inc. (NASDAQ:FENC) were recently published by: Nasdaq.com, which released: “Fennec Announces Results of Annual Meeting” on June 08, 2018. Nasdaq.com‘s article titled: “Fennec Pharmaceuticals Set to Join Russell 3000 Index” and published on June 11, 2018 is yet another important article.

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: